Biotech VC Aids Epstein Associate’s Return to Industry

A biotech investor with ties to convicted sex offender Jeffrey Epstein is making a comeback in the venture capital world, aided by Alexis Borisy, a prominent figure in the biotech industry. The resurgence of Boris Nikolic, whose association with Epstein surfaced in 2019, raises ethical questions within the sector.

Nikolic’s Past and Initial Fallout

Dr. Boris Nikolic, a Harvard-trained physician and immunologist, previously served as chief science and technology advisor to Bill Gates and co-founded Biomatics Capital Partners [1]. His connection to Epstein became public when Epstein named Nikolic as a successor executor in his will in August 2019 [1]. Nikolic publicly declined the role, stating he was “shocked,” but correspondence revealed a sustained relationship spanning roughly a decade [1]. Following the revelations, Nikolic faced industry backlash.

Borisy’s Role in the Comeback

Despite the controversy, Alexis Borisy, a highly influential biotech venture capitalist, reportedly worked to rehabilitate Nikolic’s standing within the biotech community [1], [2]. The nature of Borisy’s assistance has not been fully disclosed, but it has enabled Nikolic to re-enter the biotech investment landscape [1].

Industry Concerns and Ethical Implications

This situation has sparked concerns about the biotech industry’s response to ethical breaches and the potential for powerful individuals to shield associates from consequences [2]. The intersection of high finance and controversial figures raises questions about accountability and transparency within the pharmaceutical and biotechnology sectors [2].

FDA Approval of Leucovorin

Separately, the Food and Drug Administration (FDA) recently approved leucovorin for the treatment of methylenetetrahydrofolate reductase (MTHFR) deficiency, a rare genetic disorder, without completing traditional, large-scale clinical trials [2]. This expedited approval process adds to the broader discussion about risk assessment and public trust in the industry [2].